This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

DEST Insider Trading (Destiny Pharma plc (DEST.L))

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £7,920
Insider Selling (Last 12 Months): GBX 0

Destiny Pharma plc (DEST.L) Insider Trading History Chart

Destiny Pharma plc (DEST.L) Share Price & Price History

GBX 113
▼ -2.5 (-2.16%)
As of 02/25/2021 01:55 PM ET
Days: 30 | 90 | 365
This undiscovered CBD play is on the verge of disrupting the industry
With recent health Canada approval they are poised to explode
Read more here

Destiny Pharma plc (DEST.L) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2021Nick RodgersInsiderBuy9,000GBX 88£7,920
6/4/2018Nigel RuddInsiderBuy39,100GBX 110£43,010
See Full Table
Destiny Pharma plc (DEST.L) logo
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops XF-70 for ventilator associated pneumonia/cystic fibrosis/bronchiectasis; DPD-207 for eye infections caused by bacteria and fungi; and XF drugs for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. The company has a collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel antimicrobial candidates from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More

Today's Range

Now: GBX 113
113
118

50 Day Range

MA: GBX 114.08
89
127

52 Week Range

Now: GBX 113
29.10
137

Volume

12,499 shs

Average Volume

146,831 shs

Market Capitalization

£67.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Destiny Pharma plc (DEST.L)?

Destiny Pharma plc (DEST.L)'s top insider investors include:
  1. Nick Rodgers (Insider)
Are you looking for the next great pet stock play?
Don't miss this opportunity as FRPT is already trading over 100 dollars per share!
Read more here about the next great pet stock!